The present invention is directed to radiolabeled neurokinin-1 receptor antagonists of the formula: (See above formula) wherein: A is -CD2- or -CH2CH2-; or a pharmaceutically acceptable salt thereof, which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals; examples are [18F][2-fluorodideuteromethoxy-5-(5-trifluoromethyl-tetrazol-1-yl)-benzyl]-([2S,3S]-2-phenyl-piperidin-3-yl)-amine, and pharmaceutically acceptable salts thereof; and [18F][3-fluoroethoxy-5-(5-trifluoromethyl-tetrazol-1-yl)-benzyl]-([2S,3S]-2-phenyl-piperidin-3-yl)-amine, and pharmaceutically acceptable salts thereof.
RADIOLABELED NEUROKININ-1 RECEPTOR ANTAGONISTS